$0.54
4.53%
Nasdaq, Sep 18, 04:00 pm EDT. Closed.
ISIN
US4831191030
Symbol
KALA

Kala Pharmaceuticals, Inc. Stock price

$0.54
-0.36 40.02% 1M
-12.09 95.73% 6M
-27.26 98.06% YTD
-876.21 99.94% 1Y
-532.46 99.90% 3Y
-7,516.94 99.99% 5Y
-46,178.28 100.00% 10Y
-46,178.28 100.00% 20Y
Nasdaq, Closing price Fri, Sep 18 2026
-0.03 4.53%
ISIN
US4831191030
Symbol
KALA
Industry

Is Kala Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,134 stocks worldwide.

Key metrics

Basic
Market capitalization
$10.4m
Enterprise Value
$3.2m
Net debt
positive
Cash
$7.2m
Shares outstanding
19.3m
Valuation (TTM | estimate)
P/E
negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.2
Financial Health
Equity Ratio
-
Return on Equity
-
ROCE
-168.1%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
-
EBIT
$-15.2m
Net Income
$-10.1m
Free Cash Flow
$-19.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-
EBIT
63.1%
Net Income
72.9%
Free Cash Flow
23.9%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
$-135.9
FCF per Share
$-1.0
Short interest
2.1%
Employees
6
Rev per Employee
-

Kala Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Kala Pharmaceuticals, Inc. forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Kala Pharmaceuticals, Inc. forecast:

Hold
50%
Sell
50%

Financial data from Kala Pharmaceuticals, Inc.

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 18 18
0% 0%
-
- Research and Development Expense 6.61 6.61
71% 71%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -15 -15
63% 63%
-
Net Profit -10 -10
73% 73%
-

In millions USD.

Don't miss a Thing! We will send you all news about Kala Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kala Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
3 days ago
Founder of The LSM Group to support KALA's growth across its existing business and potential acquisitions Founder of The LSM Group to support KALA's growth across its existing business and potential acquisitions
Neutral
GlobeNewsWire
17 days ago
Agreement Grants Kala Exclusive U.S. Rights to Market and Distribute Virotek's Ophthalmology Genomic Testing Program Agreement Grants Kala Exclusive U.S. Rights to Market and Distribute Virotek's Ophthalmology Genomic Testing Program
Neutral
GlobeNewsWire
19 days ago
ARLINGTON, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kala Bio, Inc. (Nasdaq: KALA) ("Kala") and Virotek Inc. ("Virotek"), a CLIA-registered precision health and clinical genomics company, today announced that they have entered into a letter of intent (the "LOI") outlining the principal terms under which the companies intend to negotiate a definitive agreement appointing Kala as the exclusive di...
More Kala Pharmaceuticals, Inc. News

Company Profile

Kala Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Watertown, MA.

Head office United States
CEO Mr. Minkowitz
Employees 6
Founded 2009
Website www.kalarx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today